Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With Brain Glioma

NCT04943913 is registered in ClinicalTrials.gov with Shanghai Juncell Therapeutics as lead sponsor.

NCT NCT04943913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04943913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) in Patients With Brain Glioma
Lead sponsor
Shanghai Juncell Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
May 6, 2021
Completion date
May 31, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma